Johnson & Johnson (JNJ.US) today announced results for the third quarter of 2023. The company delivered strong results and significant growth progress in the third quarter, "... providing a solid foundation for future sustainable growth," - Joaquin Duato, chairman of the board and CEO of JnJ, said.
Key details of the report:
Start investing today or test a free demo
Open account Try demo Download mobile app Download mobile app- Third-quarter 2023 sales growth of 6.8% to $21.4 billion (estimated $21.03 billion), with operating growth of 6.4% and adjusted operating growth of 4.9%. Operating growth excluding COVID-19 vaccine of 9.0%.
- Earnings per share (EPS) of $1.69 increased 4.3%, and adjusted EPS of $2.66 (estimated $2.52) increased 19.3%.
- The company is raising its full-year forecasts for 2023 for sales and adjusted earnings per share (EPS).
Segment results:
Source: JNJ
Earnings forecasts have been raised:
Source: JNJ
More details on the results can be found here.
The company's shares are gaining nearly 1.3% before the opening of the session.
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
